A Phase 3, Multicenter, Randomized, Double-blind Study to Determine the Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis, in Both Acute and Maintenance Phases
Phase of Trial: Phase III
Latest Information Update: 28 Feb 2019
Price : $35 *
At a glance
- Drugs Mesalazine (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Acronyms PACE
- Sponsors Shire
- 29 Nov 2018 Status changed from active, no longer recruiting to completed.
- 10 Nov 2018 This trial was discontinued in Germany, according to European Clinical Trials Database.
- 03 Oct 2018 Planned End Date changed from 23 Oct 2020 to 26 Feb 2019.